MedinGlobal

Edit Template

CLADRIM 10MG

In Stock

CLADRIM 10MG contains Cladribine 10MG and is listed as a prescription anticancer medicine associated with the treatment of hairy cell leukemia and other selected specialist indications. It belongs to the purine nucleoside analog class and works by disrupting DNA synthesis in susceptible abnormal white blood cells. Treatment requires specialist supervision, and severe marrow suppression and infection risks require appropriate blood count monitoring.

Medinglobal provides medicine information and enquiry coordination. It does not manufacture, sell or dispense medicines directly. Availability and any subsequent supply are subject to verification by an appropriately authorised independent provider and applicable regulations.

CLADRIM 10MG – Composition, Uses and Medicine Enquiries

Product Overview

CLADRIM 10MG is listed as a prescription product containing Cladribine 10MG, marketed in the source catalogue by Fresenius Kabi India Pvt Ltd.

It belongs to the anticancer; purine nucleoside analog class and may be prescribed for hairy cell leukemia and other selected specialist indications.

Its active ingredient disrupts DNA synthesis in susceptible abnormal white blood cells.

The exact manufacturer pack, formulation, approved indication and administration schedule must be checked before treatment or publication. A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements.

Severe marrow suppression and infection risks require blood count monitoring.

Composition and Strength

The supplied product information identifies the following composition:

Active Ingredient Strength
Cladribine 10MG

Product Name: CLADRIM 10MG

Generic Name: Cladribine

Brand Name: CLADRIM 10MG

Strength: 10MG

Listed Marketer: Fresenius Kabi India Pvt Ltd

The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.

Therapeutic Category and Indication

CLADRIM 10MG belongs to the anticancer category and is classified as a purine nucleoside analog.

It may be prescribed for hairy cell leukemia and other selected specialist indications.

Cladribine works by disrupting DNA synthesis in susceptible abnormal white blood cells.

Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.

Severe marrow suppression and infection risks require blood count monitoring.

Administration Information

The supplied product information identifies intravenous administration by oncology professionals under an approved protocol.

Administration must follow the treating clinician’s instructions and the approved product label.

Patients should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.

The exact administration schedule must be verified against the approved product information.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: CLADRIM 10MG
  • Generic Name: Cladribine
  • Strength: 10MG
  • Company Name: Fresenius Kabi India Pvt Ltd
  • Therapeutic Category: Anticancer
  • Medicine Class: Purine Nucleoside Analog
  • Indication: Hairy cell leukemia and other selected specialist indications
  • Administration: Intravenous administration by oncology professionals under an approved protocol

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation require verification from original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.

Prescription and Patient Safety

CLADRIM 10MG is listed as a prescription anticancer medicine and requires specialist supervision.

Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by a qualified oncology specialist.

Severe marrow suppression and infection risks require blood count monitoring.

Patients should follow the approved product label and the treating oncology team’s instructions. The medicine should only be administered according to an approved clinical protocol.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export medicines.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a CLADRIM 10MG Enquiry

To help identify the requested product, include the following details:

  1. Product name: CLADRIM 10MG.
  2. Generic name: Cladribine.
  3. Required strength: 10MG.
  4. Required formulation and quantity.
  5. Destination country.
  6. Valid prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is CLADRIM 10MG used for?

CLADRIM 10MG is associated with hairy cell leukemia and other selected specialist indications. The treating prescriber confirms the approved use.

What is the composition of CLADRIM 10MG?

The supplied catalogue lists Cladribine 10MG as its active ingredient. The composition should be verified against the original product packaging.

How is CLADRIM 10MG administered?

The supplied information identifies intravenous administration by oncology professionals under an approved protocol.

Which company is listed for CLADRIM 10MG?

Fresenius Kabi India Pvt Ltd is listed as the marketer in the supplied product information.

Does CLADRIM 10MG require specialist supervision?

Yes. Treatment requires specialist supervision. Severe marrow suppression and infection risks require blood count monitoring.

Can Medinglobal supply CLADRIM 10MG directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “CLADRIM 10MG”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top